MX2023002362A - Tratamiento de cáncer de pulmón de células no pequeñas con mutaciones en el receptor del factor de crecimiento epidérmico (egfr). - Google Patents
Tratamiento de cáncer de pulmón de células no pequeñas con mutaciones en el receptor del factor de crecimiento epidérmico (egfr).Info
- Publication number
- MX2023002362A MX2023002362A MX2023002362A MX2023002362A MX2023002362A MX 2023002362 A MX2023002362 A MX 2023002362A MX 2023002362 A MX2023002362 A MX 2023002362A MX 2023002362 A MX2023002362 A MX 2023002362A MX 2023002362 A MX2023002362 A MX 2023002362A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- lung cancer
- egfr mutations
- small lung
- egfr
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063069748P | 2020-08-25 | 2020-08-25 | |
| PCT/IB2021/057794 WO2022043895A2 (en) | 2020-08-25 | 2021-08-25 | Treatment of non-small lung cancer with egfr mutations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023002362A true MX2023002362A (es) | 2023-05-19 |
Family
ID=80352814
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023002362A MX2023002362A (es) | 2020-08-25 | 2021-08-25 | Tratamiento de cáncer de pulmón de células no pequeñas con mutaciones en el receptor del factor de crecimiento epidérmico (egfr). |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US12528869B2 (https=) |
| EP (1) | EP4204455A4 (https=) |
| JP (1) | JP2023539589A (https=) |
| KR (1) | KR20230053686A (https=) |
| CN (1) | CN116194141A (https=) |
| AU (1) | AU2021330539A1 (https=) |
| CA (1) | CA3192922A1 (https=) |
| IL (1) | IL300854A (https=) |
| JO (1) | JOP20230039A1 (https=) |
| MX (1) | MX2023002362A (https=) |
| WO (1) | WO2022043895A2 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230174677A1 (en) * | 2021-11-16 | 2023-06-08 | Janssen Biotech, Inc. | Use of Approved Bispecific EGFR and Met Specific Antibody Drug Product to Treat Non-Small Cell Lung Cancer (NSCLCL) |
| US20240317866A1 (en) * | 2022-06-30 | 2024-09-26 | Janssen Biotech, Inc. | Use of Anti-EGFR/Anti-Met Antibody to Treat Gastric or Esophageal Cancer |
| WO2024108193A2 (en) * | 2022-11-18 | 2024-05-23 | Epibiologics, Inc. | Degradation of cmet using a bispecific binding agent |
| CN116284335A (zh) * | 2023-03-17 | 2023-06-23 | 云南中医药大学 | Egfr基因突变体的检测方法及应用 |
| WO2025158277A1 (en) * | 2024-01-22 | 2025-07-31 | Janssen Biotech, Inc. | Use of amivantamab to treat head and neck cancer |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE87659T1 (de) | 1986-09-02 | 1993-04-15 | Enzon Lab Inc | Bindungsmolekuele mit einzelpolypeptidkette. |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| ATE199392T1 (de) | 1992-12-04 | 2001-03-15 | Medical Res Council | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung |
| AUPO591797A0 (en) | 1997-03-27 | 1997-04-24 | Commonwealth Scientific And Industrial Research Organisation | High avidity polyvalent and polyspecific reagents |
| EP1766068A4 (en) | 2004-06-04 | 2010-03-03 | Genentech Inc | EGFR Mutations |
| EP1789446A2 (en) | 2004-09-02 | 2007-05-30 | Genentech, Inc. | Heteromultimeric molecules |
| EP3050963B1 (en) | 2005-03-31 | 2019-09-18 | Chugai Seiyaku Kabushiki Kaisha | Process for production of polypeptide by regulation of assembly |
| DE102005028778A1 (de) | 2005-06-22 | 2006-12-28 | SUNJÜT Deutschland GmbH | Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage |
| US8871912B2 (en) | 2006-03-24 | 2014-10-28 | Merck Patent Gmbh | Engineered heterodimeric protein domains |
| WO2007147901A1 (en) | 2006-06-22 | 2007-12-27 | Novo Nordisk A/S | Production of bispecific antibodies |
| KR20100058509A (ko) | 2007-07-31 | 2010-06-03 | 메디뮨 엘엘씨 | 다중특이적 에피토프 결합 단백질 및 이의 용도 |
| US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
| US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
| US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
| US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| JP2012525149A (ja) | 2009-04-27 | 2012-10-22 | オンコメッド ファーマシューティカルズ インコーポレイテッド | ヘテロ多量体分子を作製するための方法 |
| EP3511342B1 (en) | 2010-03-10 | 2024-01-17 | Genmab A/S | Monoclonal antibodies against c-met |
| DK2560993T3 (da) | 2010-04-20 | 2024-10-14 | Genmab As | Heterodimeric antibody fc-containing proteins and methods for production thereof |
| PL2635607T3 (pl) | 2010-11-05 | 2020-05-18 | Zymeworks Inc. | Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC |
| WO2012142535A2 (en) | 2011-04-15 | 2012-10-18 | Esco Corporation | Replaceable wear parts for an earth-working roll |
| CA2854233C (en) | 2011-11-04 | 2020-05-12 | Zymeworks Inc. | Stable heterodimeric antibody design with mutations in the fc domain |
| US20170275367A1 (en) | 2012-11-21 | 2017-09-28 | Janssen Biotech, Inc. | Bispecific EGFR/C-Met Antibodies |
| CN113201073A (zh) * | 2012-11-21 | 2021-08-03 | 詹森生物科技公司 | 双特异性EGFR/c-Met抗体 |
| EP3029067A1 (en) | 2014-12-01 | 2016-06-08 | Deutsches Krebsforschungszentrum | Use of blocking-reagents for reducing unspecific T cell-activation |
| IL319047A (en) | 2015-08-28 | 2025-04-01 | Amunix Operating Inc | Chimeric polypeptide composition and methods for its preparation and use |
| MA46852A (fr) | 2016-11-17 | 2019-09-25 | Univ Texas | Composés à activité antitumorale contre des cellules cancéreuses porteuses de mutations egfr ou her2 exon 20 |
| WO2020102647A1 (en) | 2018-11-15 | 2020-05-22 | Invenra Inc. | Multivalent receptor-clustering agonist antibody constructs and antigen binding proteins |
| SG11202108311RA (en) | 2019-02-26 | 2021-09-29 | Janssen Biotech Inc | Combination therapies and patient stratification with bispecific anti-egfr/c-met antibodies |
| WO2020230091A1 (en) | 2019-05-14 | 2020-11-19 | Janssen Biotech, Inc. | Combination therapies with bispecific anti-egfr/c-met antibodies and third generation egfr tyrosine kinase inhibitors |
| IL305700A (en) | 2021-03-09 | 2023-11-01 | Janssen Biotech Inc | Treatment of cancers lacking EFGR-activating mutations |
-
2021
- 2021-08-25 IL IL300854A patent/IL300854A/en unknown
- 2021-08-25 WO PCT/IB2021/057794 patent/WO2022043895A2/en not_active Ceased
- 2021-08-25 MX MX2023002362A patent/MX2023002362A/es unknown
- 2021-08-25 US US17/411,158 patent/US12528869B2/en active Active
- 2021-08-25 JP JP2023513309A patent/JP2023539589A/ja active Pending
- 2021-08-25 KR KR1020237009896A patent/KR20230053686A/ko active Pending
- 2021-08-25 CN CN202180052496.5A patent/CN116194141A/zh active Pending
- 2021-08-25 AU AU2021330539A patent/AU2021330539A1/en active Pending
- 2021-08-25 CA CA3192922A patent/CA3192922A1/en active Pending
- 2021-08-25 EP EP21860686.1A patent/EP4204455A4/en active Pending
-
2023
- 2023-02-23 JO JOJO/P/2023/0039A patent/JOP20230039A1/ar unknown
-
2025
- 2025-11-14 US US19/389,439 patent/US20260070993A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3192922A1 (en) | 2022-03-03 |
| US20260070993A1 (en) | 2026-03-12 |
| EP4204455A2 (en) | 2023-07-05 |
| JP2023539589A (ja) | 2023-09-15 |
| WO2022043895A3 (en) | 2022-06-09 |
| KR20230053686A (ko) | 2023-04-21 |
| WO2022043895A2 (en) | 2022-03-03 |
| WO2022043895A8 (en) | 2023-03-09 |
| CN116194141A (zh) | 2023-05-30 |
| AU2021330539A1 (en) | 2023-05-04 |
| IL300854A (en) | 2023-04-01 |
| US12528869B2 (en) | 2026-01-20 |
| JOP20230039A1 (ar) | 2023-02-23 |
| AU2021330539A9 (en) | 2023-07-13 |
| EP4204455A4 (en) | 2024-10-16 |
| US20220064306A1 (en) | 2022-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023002362A (es) | Tratamiento de cáncer de pulmón de células no pequeñas con mutaciones en el receptor del factor de crecimiento epidérmico (egfr). | |
| MX2019005834A (es) | Compuestos con actividad antitumoral contra células cancerosas que tienen mutaciones en el exón 20 de egfr o her2. | |
| MA42999B1 (fr) | Polythérapie contenant ivosidenib, cytarabine et daunorubicin ou idarubicin pour le traitement de la leucémie myéloïde aiguë | |
| EP4234551A3 (en) | Pyridazinones as parp7 inhibitors | |
| ZA202001445B (en) | Exon 18 and/or exon 21 mutant egfr selective inhibitor | |
| PH12021552395A1 (en) | Compounds with anti-tumor activity against cancer cells bearing egfr or her2 exon 20 insertions | |
| PH12022552076A1 (en) | TREATMENT OF PATIENTS HAVING c-MET EXON 14 SKIPPING MUTATIONS | |
| HK1250638A1 (zh) | 治疗egfr突变的癌症的方法 | |
| EP4434530A3 (en) | Vcn enhancer compositions and methods of using the same | |
| MX2021011488A (es) | Compuestos y usos de estos. | |
| EP4353320A3 (en) | Blood plasma and plasma fractions as therapy for tumor growth and progression | |
| WO2020055643A3 (en) | Compounds, compositions and methods for treating or preventing her-driven cancers | |
| MA40075A (fr) | Combinaisons pour traiter des cancers | |
| JOP20210264A1 (ar) | مركبات نورجولين-4 وطرق استخدامها | |
| MX2021008834A (es) | Metodos de tratamiento del cancer de mama con tucatinib. | |
| MX2025002424A (es) | Combinacion de dcc-3116 e inhibidores de la via mapkap para su uso en el tratamiento del cancer | |
| MX2023006087A (es) | Formulaciones liofilizadas de tegavivint. | |
| ZA202104679B (en) | L718 and/or l792 mutant treatment-resistant egfr inhibitor | |
| MX2022002607A (es) | Metodos de tratamiento. | |
| BR112023018278A2 (pt) | Tratamento de cânceres sem mutações de ativação de egfr | |
| MX2024005589A (es) | Combinaciones de lurbinectedina y atezolizumab. | |
| EP4132657A4 (en) | COMPOSITIONS AND METHODS FOR TREATING ANTICANCER-RESISTANT CANCER | |
| WO2024186883A3 (en) | Compositions and methods for the treatment of human papillomavirus-driven cancers | |
| WO2019032810A3 (en) | Methods and materials for identifying and treating bet inhibitor-resistant cancers | |
| BR112023020562A2 (pt) | Métodos de tratamento de carcinoma pulmonar de células não pequenas com o uso de telisotuzumabe vedotina |